Can doctors make a stem cell transplant tougher against cancer while protecting the healthy blood-forming cells patients desperately need?
That is the hard question behind new research from Washington University School of Medicine in St. Louis on gene-edited stem cell transplants for aggressive blood cancers.
The short version is hopeful, but we need to keep both feet on the ground.
A phase 1/2 multicenter clinical trial tested donor stem cells edited with CRISPR to remove a protein called CD33 before transplant in adults with acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS, who were at high risk of relapse.1
This is not a cure announcement.
It is a serious early clinical step that may help solve one of the biggest problems in treating myeloid blood cancers: how to attack cancer cells without destroying the healthy blood system in the process.
Gene-Edited Stem Cell Transplants: The Core Idea
A standard stem cell transplant can be one of the few potentially curative options for highly aggressive blood cancers, yet AML and MDS can still return after transplant.1
That is the brutal part of the story: patients can go through a major procedure and still face relapse.
The WashU-led trial tested whether donor stem cells could be edited before transplant so they no longer carry CD33, a protein found on many myeloid cells.1
The edited cell product is called tremtelectogene empogeditemcel, or trem-cel, and the study was funded by Vor Biopharma.1
Think of CD33 like a jersey number.
If cancer cells and healthy donor stem cells both wear the same jersey, a CD33-targeted therapy can hit both teams.
The researchers wanted healthy donor cells to take off that jersey, so future CD33-targeted therapy could aim at cancer cells while sparing the transplanted blood-forming system.
Why CD33 Matters in AML and MDS
AML and MDS are myeloid cancers, which makes them hard targets for some immunotherapies.1
The reason is simple and frustrating: the proteins that can help immune therapies recognize cancer are also found on healthy myeloid cells, including donor stem cells used in transplant.1
WashU Medicine explained that CD33-targeted CAR-T cell therapy has been difficult in AML and MDS because attacking CD33 can also damage healthy blood-forming cells.1
That can trigger serious toxicity and may weaken the cancer-killing effect because immune cells spend energy hitting healthy targets instead of cancer cells.1
This is where gene editing enters the room like a locksmith instead of a sledgehammer.
Rather than only building a stronger attack, researchers are trying to protect the healthy cells first.
What the Trial Actually Tested
The clinical trial enrolled 30 adult patients with AML or MDS who were at high risk of relapse.1
Each patient received donor stem cells in which CD33 had been removed using CRISPR gene editing before the transplant procedure.1
After transplant, patients also received a maintenance therapy that targets CD33, called gemtuzumab ozogamicin, as proof of concept.1
Gemtuzumab ozogamicin is an engineered antibody that targets CD33 and carries an anti-cancer drug.1
The drug is approved by the U.S. Food and Drug Administration for CD33-positive AML and is being studied in CD33-positive MDS.1
WashU Medicine reported that the maintenance drug can help prevent relapse, but its use can be limited by liver toxicity and blood cell damage, including low white blood cells, red blood cells, and platelets.1
| Trial feature | Verified detail |
|---|---|
| Study type | Phase 1/2 multicenter clinical trial |
| Patients | 30 adults with AML or MDS at high risk of relapse |
| Stem cell change | Donor stem cells edited with CRISPR to remove CD33 |
| Cell product | Tremtelectogene empogeditemcel, or trem-cel |
| Post-transplant therapy | Gemtuzumab ozogamicin, a CD33-targeted antibody-drug therapy |
| Published | May 12, 2026 in Nature Medicine |
The Main Results Patients Should Understand
All 30 patients achieved engraftment by day 28, meaning the transplanted cells reached the bone marrow and began working.1
Some patients achieved this sooner, and platelet production returned by day 16 on average, which WashU Medicine said was comparable to standard transplanted stem cells.1
Average survival was just over 14 months.1
Nineteen patients received at least one cycle of the CD33-targeted antibody maintenance therapy as part of a dose-escalation protocol, and researchers established the recommended dose.1
The researchers also found that patients maintained blood cell counts across all doses, suggesting the gene-edited transplant helped protect them from the dangerously low blood counts often seen when this maintenance therapy follows a standard transplant.1
This matters because blood counts are not just numbers on a lab sheet.
They are the body’s infantry, supply chain, and repair crew.
What About Side Effects?
The side effects reported during treatment were similar to those seen with standard stem cell transplants.1
They included anemia, low platelets, fever, infections, and graft-versus-host disease, which happens when donor cells attack a patient’s healthy tissues.1
Seven patients died during the study.1
Four deaths were due to cancer progression, and three were related to transplant causes, including kidney failure, liver toxicity, and sepsis.1
That is why we cannot turn this into hype.
The science is promising, but these are very sick patients facing very high-risk disease, and stem cell transplant remains a heavy medical intervention.
Why This Could Help Future CAR-T Therapy
The big long-term goal is not only the transplant itself.
The goal is to create a protected blood system that can survive future CD33-targeted therapy.
According to WashU Medicine, Dr. John F. DiPersio said the results lay the groundwork for pairing CD33-deleted stem cell transplant with CD33-targeted immunotherapies that avoid destroying healthy donor cells.1
That could matter for CAR-T therapy.
CAR-T therapy has changed care for some blood cancers, but AML and MDS have been harder because the cancer and healthy blood cells can share the same targets.1
For readers who want a broader patient-friendly background, our guide to stem cell therapy vs. bone marrow transplant explains why transplant is such a major procedure.
We have also covered how stem cell therapy and gene therapy differ, which is useful here because this study sits at the crossroads of both fields.
The Earlier Case Study Behind the Strategy
WashU Medicine also noted a related single-patient case study published in October 2025 in JCO Precision Oncology.1
In that case, a patient with high-risk AML received a CD33-deleted stem cell transplant and later received CD33-targeted CAR-T cell therapy after relapse.1
The patient achieved complete remission and remained cancer free more than one year after CAR-T therapy, according to WashU Medicine.1
The patient also had normal blood cell production return, and all blood cells lacked CD33, suggesting the edited donor cells had established themselves in the bone marrow.1
That case is encouraging, but it is still one case.
One case can point to a door, but it does not prove the whole road is safe.
What This Does Not Mean
This does not mean gene-edited stem cell transplants are available for every person with AML or MDS.
This does not mean CD33-targeted CAR-T is now proven for these cancers.
This does not mean risk disappears because CRISPR is involved.
It means researchers are testing a smart strategy: protect healthy donor stem cells first, then make it easier to target cancer later.
That is a much more disciplined story than “gene editing cures cancer.”
Patients deserve the disciplined story.
How This Fits Into Regenerative Medicine
Regenerative medicine is often described as rebuilding or repairing damaged systems.
In this case, the repair target is the blood-forming system itself.
The edited transplant is designed to rebuild blood formation with donor cells that are missing CD33.1
If that works reliably, it could give doctors a cleaner shot at cancer cells that still carry CD33.
This is why manufacturing, gene editing, transplant medicine, and cancer immunotherapy are starting to overlap.
It is also why our coverage of the future of gene editing remains relevant for patients tracking where the field is moving.
Questions Patients Should Ask Their Care Team
Patients with AML or MDS should never chase this kind of news without a specialist guiding the conversation.
The right move is not panic-shopping for experimental treatment online.
| Question | Why it matters |
|---|---|
| Am I eligible for a standard stem cell transplant? | Eligibility depends on disease status, age, donor match, and overall health. |
| Is my cancer CD33-positive? | CD33 is central to this research strategy. |
| Are there clinical trials for my diagnosis? | Trials may be the only way to access investigational approaches. |
| What are the transplant risks in my case? | Risks vary widely by patient and disease. |
| How strong is the evidence for this option? | Early trial data should be weighed differently than approved therapy data. |
For broader safety thinking, our guide on questions to ask a stem cell therapy provider can help patients stay grounded.
The same principle applies here: hope is good, but receipts matter.
The Bottom Line for Blood Cancer Patients
Gene-edited stem cell transplants may help make future CD33-targeted treatment safer for aggressive blood cancers like AML and MDS.
The new trial showed that all 30 patients achieved engraftment by day 28 after receiving CD33-deleted donor stem cells.1
It also suggested patients could maintain blood cell counts while receiving CD33-targeted maintenance therapy.1
That is meaningful.
But it is still early, and the risks are real.
The best takeaway is not “we are done.”
The best takeaway is “the playbook is getting smarter.”
